Skip to main content
SpringerLink
Log in

A Review of the Clinical Studies with Nilutamide

  • Conference paper
Antiandrogens in Prostate Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

The currently available antiandrogens are of two types: steroidal and non-steroidal (pure). The first group not only interferes with the cellular androgen receptor but also displays some progestagen-like antigonadotrophic activity. Cyproterone acetate (CPA) is the best known of these. The second group, the pure antiandrogens, displaces T from the androgen receptor, lifting the negative feedback of T to the hypothalamic pituitary level; this leads to a compensatory rise of LH resulting in an increase in T production and secretion. Although there has been concern that this rise in T levels might override the blocking effects of pure antiandrogens, several reports have shown this not to be true.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Decensi AU, Boccardo F, Guarneri D et al: Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991 (146): 377–381

    PubMed  CAS  Google Scholar 

  2. Decensi AU, Torrisi K, Fontana V et al: Long term endocrine effects of administration of either a nonsteroidal antiandrogen or a luteinizing hormonereleasing hormone agonist in men with prostate cancer. Acta Endocrinol 1993 (129): 315–321

    PubMed  CAS  Google Scholar 

  3. Bertagna C, de Géry A, Hucher M, Francois JP, Zanirato J: Efficacy of the combination of Anandron (nilutamide) with orchidectomy in metastatic cancer. A metaanalysis of seven randomized double-blind trials (1191 patients). Br J Urol 1994 (in press)

    Google Scholar 

  4. Akaza H, Aso Y, Niijima T et al: Clinical study of RU 23908 (nilutamide) in prostatic cancer. Hinyokika Kiyo 1991 (37): 407–420

    PubMed  CAS  Google Scholar 

  5. Le Duc A, Arvis G, Ballanger R et al: Comparaison de l’efficacité du nilutamide (Anandron) à un placebo sur les douleurs des métastases osseuses de cancer de la prostate. Progrès en Urologie 1992 (suppl 2): 24–30

    Google Scholar 

  6. Labrie F, Dupont A, Bélanger A et al: New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983 (4): 579–594

    Article  PubMed  CAS  Google Scholar 

  7. Labrie F, Dupont A, Bélanger A et al: Traitement anti-androgénique combiné dans l’adénocarcinome de la prostate: première application d’un nouveau principe thérapeutique efficace dans le cancer hormono-dépendant. Annales d’Urologie 1986 (20): 98–106

    PubMed  CAS  Google Scholar 

  8. Kuhn J-M, Billebaud T, Navratil H et al: Prevention of the transient adverse effects of a gonadotrophinreleasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an antiandrogen nilutamide. N Engl J Med 1989 (321): 413–418

    Article  PubMed  CAS  Google Scholar 

  9. Navratil H: Double blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin: results on 49 cases from a multicentre study. In: Murphy G, Khoury S, Kuss P, Chatelain C and Denis L (eds) Prostatic Cancer. Part A. Alan R Liss, New York 1987 pp 401–410

    Google Scholar 

  10. Navratil H: Preliminary clinical evaluation of leuprolin acetate depot injection in France, in the management of prostatic cancer. J Internat Med Res 1990 (18 suppM): 69–73

    Google Scholar 

  11. Migliari R, Scarpa RM, Campus G et al: Evaluation of efficacy and tolerability of nilutamide and buserelin in the treatment of advanced prostate cancer. Archivio Italiano di Urologia Andrologia 1991 (63): 147–153

    CAS  Google Scholar 

  12. Crawford ED, Smith Jr, Soloway MS et al: Treatment of stage D2 prostatic cancer with leuprolide and Anandron compared to leuprolide and placebo. In: Murphy G et al (eds) Recent Advances in Urological Cancers and Diagnosis and Treatment. Paris, 1990 pp 61-62

    Google Scholar 

  13. Brisset JM, Boccon-Gibod L, Botto H et al: Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer. Part A: Research, endocrine treatment and histopathology. Alan R Liss, New York 1987 pp 411–422

    Google Scholar 

  14. Namer M, Teubel J, Caby A et al: A ransomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Ster Biochem Mol Biol 1990 (37): 909–915

    Article  CAS  Google Scholar 

  15. Béland G, Elhilali M, Fradet Y et al: Total androgen ablation: Canadian experience. Urologic Clinics of North America 1991 (18): 75–82

    PubMed  Google Scholar 

  16. Janknegt RA, Abbou CC, Bartoletti R et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993 (149): 77–83

    PubMed  CAS  Google Scholar 

  17. Smith JA, Crawford ED, Lange PH et al: PSA. Correlation with response and survival in advanced carcinoma of the prostate. In: Abstract book AUA San Antonio 1993 # 868

    Google Scholar 

  18. Abbou C, Brisset JM, Bracken B et al: Prostate specific antigen prognostic value for response to treatment in stage D2 prostate cancer patients: evaluation in a large study (457 patients) with central PSA assay. European Urology Xth EAU Congress, Genoa 22-25 July 1992, abstract # 267

    Google Scholar 

  19. Harnois C, Malenfant M, Dupont A, Labrie F: Ocular toxicity of anandron in patients treated for prostatic cancer. Br J Ophtalmol 1986 (70): 471–473

    Article  CAS  Google Scholar 

  20. Boccardo F, Decensi AU, Guarneri D et al: Anandron (RU 23908) in metastatic prostate cancer: Preliminary results of multicentric Italian study. Cancer Detect Prevent 1991 (15): 501–503

    PubMed  CAS  Google Scholar 

  21. Hammel P, Ducreux M, Bismuth E et al: Acute hepatitis related to the use of nilutamide (Anadron®). Gastroenterologie Clinique et Biologique 1991 (15): 557

    PubMed  CAS  Google Scholar 

  22. Gomez JL, Dupont A, Cusan L et al: Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. Am J Med 1992 (92): 563–566

    Article  PubMed  CAS  Google Scholar 

  23. Seigneur J, Trechot PF, Hubert J: Pulmonary complications of hormone treatment in prostate carcinoma. Chest 1988 (93): 1106

    Article  PubMed  CAS  Google Scholar 

  24. Pfitzenmeyer P, Foucher P, Piard F et al: Nilutamide pneumonitis: a report on 8 patients. Thorax 1992 (47): 622–627

    Article  PubMed  CAS  Google Scholar 

  25. Jonville AP, Diot E, Dutertre JP, Autret E: Toxicité pulmonaire du nilutamide (Anadron®). Bilan Coopératif des Centres Français de Pharmacovigilance. Therapie 1992 (47): 393–397

    PubMed  CAS  Google Scholar 

  26. Camus P; Coudert B, D’Athis P et al: Pharmacokinetics and metabolism of nuutamide in the isolated rat lung. J Pharmacol Exper Ther 1991 (259): 1247–1255

    CAS  Google Scholar 

  27. Moorjani S, Dupont A, Labrie F et al: Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 1987 (36): 244–250

    Article  PubMed  CAS  Google Scholar 

  28. Brisset JM: Nilutamide (Anandron®) in prostate cancer: Review of four clinical trials. In: Khoury S, Chatelain C, Denis L (eds) Urology. Prostate Cancer. Fiis et RGP, Paris 1990 pp 381-389

    Google Scholar 

  29. Du Plessis DDJ: Castration plus nilutamide vs castration plus placebo in advanced prostate cancer: a review. Urology 1991 (37 suppl 2): 20–24

    Article  Google Scholar 

  30. Knönagel H, Bolle JF, Hering F et al: Die Therapie des metastasierten Prostatakarzinoms durch Orchiektomie plus Anandron versus Orchiektomie plus Placebo. Erste Ergebnisse einer randomisierten Multizenterstudie. Helv Chir Acta 1989 (56): 343–345

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, A.Z. Middelheim, Lindendreef 1, 2020, Antwerp, Belgium

    Charles Mahler

Authors
  1. Charles Mahler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncologisch Centrum Antwerpen, Algemeen Ziekenhuis Middelheim, Vrije Universiteit Brussel, Lindendreef 1, 2020, Antwerp, Belgium

    Louis Denis

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Mahler, C. (1996). A Review of the Clinical Studies with Nilutamide. In: Denis, L. (eds) Antiandrogens in Prostate Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45745-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45745-6_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45747-0

  • Online ISBN: 978-3-642-45745-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation